Clinical Efficacy and Safety of Aidi Injection Plus Docetaxel-Based Chemotherapy in Advanced Nonsmall Cell Lung Cancer: A Meta-Analysis of 36 Randomized Controlled Trials

Table 1

Characteristics of included studies.

First author. year	NSCLC(III-IV)			Randomized Method	Interventions		C	Scale(A)	Scale(B)	Follow-up	Outcomes
	E/C	M/F	Age		E	Aidi(D/T/C)
Bian, M. 2006 [32]	34/30	44/20	30-75	Unclear	Aidi + DP	50 ml/15d/2	DP	WHO	WHO	8 w	O1, O2, O3
Zhu, Q. 2006 [33]	30/30	32/28	33-74	Randomized digital table	Aidi + DP	50 ml/10d/3	DP	RECIST	WHO	9 w	O1, O2, O3
Chen, X. 2007 [22]	32/32	39/25	47-72	Unclear	Aidi + DP	50 ml/15-20d/2	DP	WHO	WHO	6 w	O1, O2, O3
Hou, E. 2008 [34]	35/35	41/29	34-70	Unclear	Aidi + DP	50 ml/10d/2	DP	WHO	WHO	6 w	O1, O2, O3
Jiang, L. 2008 [35]	50/50	69/31	39-76	Unclear	Aidi + DP	50 ml/21d/-	DP	WHO	WHO	4 w	O1, O2, O3
Lin, Q. 2008 [36]	30/30	41/19	35-73	Unclear	Aidi + DP	50 ml/14d/2	DP	WHO	WHO	6 w	O1, O2, O3
Wang, H. 2008 [37]	40/40	51/29	30-70	Unclear	Aidi + DP	80-100 ml/14d/2	DP	WHO	WHO	6 w	O1, O2, O3
Cui, H. 2010 [38]	30/30	39/21	38-76	Unclear	Aidi + DP	80-100 ml/8w/1	DP	WHO	WHO	8 w	O1, O2, O3
Du, Z. 2011 [23]	60/60	94/26	42-71	Unclear	Aidi + DP	40 ml/20d/2	DP	WHO	WHO	8 w	O1, O2, O3
Lin, S. 2011 [39]	42/40	52/30	32-79	Unclear	Aidi + DP	50 ml/14d/2	DP	WHO	WHO	4 w	O1, O2, O3
Tang, L. 2011 [40]	25/25	28/22	37-74	Unclear	Aidi + DP	50 ml/14d/2	DP	RECIST	WHO	4 w	O1, O2, O3
Wang, T. 2011 [41]	49/49	65/33	30-78	Unclear	Aidi + DP	80-100 ml/14d/2	DP	WHO	WHO	6 w	O1, O2, O3
Xing, H. 2011 [42]	35/35	42/28	60-82	Unclear	Aidi + TXT	50 ml/15d/2	TXT	WHO	WHO	10 w	O1, O2, O3
Jiang, S. 2012 [43]	23/23	38/8	43-70	Randomized digital table	Aidi + DP	50 ml/14d/2	DP	WHO	WHO	6 w	O1, O3
Shi, L. 2012 [44]	38/38	55/21	38-72	Unclear	Aidi + DP	100 ml/14d/2	DP	WHO	No	6 w	O1, O2
Tang, X. 2012 [45]	36/40	42/34	38-73	Randomized digital table	Aidi + DP	50 ml/14d/2	DP	RECIST	WHO	6 w	O1, O3
Chen, Z. 2013 [24]	52/54	72/34	57-78	Lottery	Aidi + DP	50 mL/12W/-	DP	RECIST	No	12 w	O1, O2
Ge, C. 2013 [46]	41/39	52/28	53-77	Unclear	Aidi + DP	50 mL/4W/-	DP	WHO	WHO	4 w	O1, O3
Wu. Y. 2013 [47]	19/19	21/17	31-68	Unclear	Aidi + DP	60 ml/10d/2	DP	WHO	WHO	6 w	O1, O2, O3
Gao, E. 2014 [48]	36/35	37/34	Unclear	Unclear	Aidi + DP	50 ml/14d/3	DP	Unclear	No	9 w	O1, O2
Li, J. 2014 [49]	25/26	19/17	42-75	Unclear	Aidi + DO	100 ml/10d/3	DO	WHO	WHO	12 w	O1, O3
Song, L. 2014 [50]	32/32	41/23	27-75	Unclear	Aidi + DC	50 ml/21d/2	DC	WHO	NCI-CTC 2.0	6 w	O1, O3
Tang, Y. 2014 [51]	47/44	45/46	46-71	Randomized digital table	Aidi + DO	50 ml/14d/3	DO	WHO	NCI-CTC 3.0	3 y	O1, O3
Xing, G. 2014 [52]	72/63	92/43	Unclear	Unclear	Aidi + DL	100 ml/14d/1-6	DL	WHO	WHO	3 y	O1, O3
Xu, H. 2014 [53]	23/23	24/22	52-74	Unclear	Aidi + DP	50 ml/42d/2	DP	WHO	WHO	6 w	O1, O3
Gao, Y. 2015 [54]	40/48	59/29	32-78	Unclear	Aidi + DP	80 mL/14d/3	DP	RECIST	WHO	9 w	O1, O3
Li, Z. 2015 [56]	25/25	37/13	65-80	Unclear	Aidi + TXT	50 ml/10d/1	TXT	No	Unclear	Unclear	O2
Hu, Q. 2015 [55]	35/35	41/29	34-76	Randomized digital table	Aidi + DC	50 ml/14d/2	DC	WHO	WHO	6 w	O1, O3
Wang, J. 2015 [58]	50/50	58/42	35-76	Unclear	Aidi + DP	80-100 ml/14d/2	DP	WHO	No	6 w	O1, O2
Mo, Y. 2015 [57]	43/43	49/37	Unclear	Randomized digital table	Aidi + DP	50 ml/14d/1	DP	WHO	WHO	6 w	O1, O2, O3
Wang, L. 2015 [59]	60/60	74/46	62-78	Randomized digital table	Aidi + TXT	50 ml/21d/1	TXT	WHO	WHO	Unclear	O1, O2, O3
Gao, Y. 2016 [60]	50/50	54/36	32-78	Unclear	Aidi + DN	80 mL/14d/3	DN	RECIST	WHO	9 w	O1, O3
He, Z. 2016 [61]	39/39	27/51	46-70	Randomized digital table	Aidi + DC	-/14d/-	DC	WHO	WHO	Unclear	O1, O3
Wang, Y. 2016 [63]	23/23	Unclear	40-70	Unclear	Aidi + DP	50 ml/10d/2	DP	RECIST	WHO	6 w	O1, O3
Wang, X. 2016 [62]	37/36	53/20	Unclear	Unclear	Aidi + DP	100 ml/7d/2	DP	no	WHO	6 w	O3
Zhu, J. 2017 [64]	84/84	95/73	31-75	Unclear	Aidi + DC	50 ml/14d/1	DC	WHO	WHO	6 w	O1, O3

Note: NSCLC: nonsmall cell lung cancer; E/C: experimental group (Aidi injection plus docetaxel-based chemotherapy) /control group (docetaxel-based chemotherapy); M/F: male/female; Aidi (D/T/C): dose/time/cycles; TXT: docetaxel; DP: docetaxel and cisplatin; DC: docetaxel and carboplatin; DO: docetaxel and oxaliplatin; DL: docetaxel and lobaplatin; DN: docetaxel and nedaplatin; scale. A: evaluation criteria of tumor response; scale. B: evaluation criteria of acute/chronic toxicity; RECIST: response evaluation criteria in solid tumors; NCI-CTC: National Cancer Institute Common Toxicity Criteria; O: outcomes; O1: ORR and DCR; O2: QOL; O3: acute /chronic toxicity.